Chardan Capital reiterated their hold rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a report released on Monday morning, AnalystRatings.com reports. The brokerage currently has a $30.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on the stock. BidaskClub raised shares of Assembly Biosciences from a sell rating to a hold rating in a research note on Friday, March 29th. Zacks Investment Research raised shares of Assembly Biosciences from a hold rating to a buy rating and set a $24.00 price objective for the company in a research note on Thursday, February 21st. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $43.00.

NASDAQ ASMB opened at $14.78 on Monday. Assembly Biosciences has a 12 month low of $13.13 and a 12 month high of $48.91.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($1.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.12). Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. The company had revenue of $3.74 million for the quarter, compared to analyst estimates of $3.69 million. As a group, sell-side analysts expect that Assembly Biosciences will post -4.61 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. United Services Automobile Association purchased a new stake in shares of Assembly Biosciences during the 3rd quarter worth about $1,902,000. BlueMountain Capital Management LLC grew its holdings in shares of Assembly Biosciences by 100.3% during the 3rd quarter. BlueMountain Capital Management LLC now owns 14,601 shares of the biopharmaceutical company’s stock worth $542,000 after purchasing an additional 7,313 shares during the period. Man Group plc boosted its holdings in Assembly Biosciences by 19.6% in the 3rd quarter. Man Group plc now owns 36,042 shares of the biopharmaceutical company’s stock worth $1,338,000 after acquiring an additional 5,904 shares during the period. Marshall Wace LLP purchased a new position in Assembly Biosciences in the 3rd quarter worth approximately $11,224,000. Finally, Victory Capital Management Inc. boosted its holdings in Assembly Biosciences by 3.4% in the 4th quarter. Victory Capital Management Inc. now owns 530,909 shares of the biopharmaceutical company’s stock worth $12,009,000 after acquiring an additional 17,669 shares during the period. 83.77% of the stock is owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Recommended Story: Risk Tolerance and Your Investment Decisions

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.